Sterling Pharma Solutions in the news

CDMOs must adapt their traditional models to meet evolving market demands, focusing on flexible resources, strategic partnerships, and integrated global operations.

Sterling Pharma Solutions is forecasting a recovery by 2026 after a difficult year marked by a 28% revenue drop and significant operating losses.

Karl Rotthier will take over as CEO of Sterling Pharma Solutions in October 2025 following the retirement of Kevin Cook.

Soligenix successfully transitioned the active ingredient manufacturing for its lymphoma and psoriasis treatments to Sterling Pharma Solutions' U.S. facility.

Sterling Pharma Solutions is funding graduate research at the University of Wisconsin-Milwaukee to support the development of cancer treatments and mental health therapies.

Sterling Pharma Solutions is reporting a recovery in sales and profitability after a challenging financial year marked by declining revenues and a shift to an operational loss.

White & Case advised lenders including HSBC and Permira Credit on the debt refinancing for Sterling Pharma Solutions.

Soligenix partnered with Sterling Pharma Solutions to optimize and scale up manufacturing of synthetic hypericin, the active ingredient in its skin cancer and psoriasis treatments.

Sterling Pharma Solutions is investing $3 million in its Germantown plant to expand ADC and high-potency API manufacturing capabilities.

Sterling Pharma Solutions has appointed Dr Mathew Minardi as President of US Operations following its acquisition of a North Carolina facility.

GHO Capital and Partners Group invested in Sterling Pharma Solutions to support its growth, capacity expansion, and strategic acquisitions.

Partners Group and GHO Capital are investing in Sterling Pharma Solutions to expand its global API manufacturing capacity and pursue further acquisitions.

GHO Capital and Partners Group invested in Sterling Pharma Solutions at a valuation of nearly £500 million.

Sterling Pharma Solutions' partnership with Northumbria University on a Knowledge Transfer Partnership (KTP) excelled in developing biocatalysis expertise, leading to new commercial opportunities and an expanded service offering.

Sterling Pharma Solutions is investing $2.1 million to expand its North Carolina site's laboratory capacity and hire 20 new scientists for early-phase drug development.

Sterling Pharma Solutions is investing $13 million to expand its Dudley facility with new labs, a large hydrogenator, and biocatalysis capabilities.

Sterling Pharma Solutions acquired Alcami's former API plant in Germantown, Wisconsin, to enhance its U.S. manufacturing capabilities for small-molecule active pharmaceutical ingredients.

Sterling Pharma Solutions acquired a North Carolina facility from CiVentiChem to establish its first U.S. presence and enhance service to its predominantly North American customer base.

Sterling Pharma Solutions received a regional award for its extensive staff training and apprenticeship programs in partnership with Derwentside College.

Sterling Pharma Solutions launched as an independent CDMO following a management buyout of a legacy API manufacturing site in the U.K. from Strides Shasun.